[go: up one dir, main page]

AR079556A1 - Formacion de anticuerpos - Google Patents

Formacion de anticuerpos

Info

Publication number
AR079556A1
AR079556A1 ARP100104778A ARP100104778A AR079556A1 AR 079556 A1 AR079556 A1 AR 079556A1 AR P100104778 A ARP100104778 A AR P100104778A AR P100104778 A ARP100104778 A AR P100104778A AR 079556 A1 AR079556 A1 AR 079556A1
Authority
AR
Argentina
Prior art keywords
formulation
antibody
effective amount
methods
therapeutically effective
Prior art date
Application number
ARP100104778A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR079556A1 publication Critical patent/AR079556A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1412—Containers with closing means, e.g. caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2003—Accessories used in combination with means for transfer or mixing of fluids, e.g. for activating fluid flow, separating fluids, filtering fluid or venting
    • A61J1/2006—Piercing means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Fluid Mechanics (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La presente provee una formulacion farmacéutica acuosa estable que comprende una cantidad terapéuticamente eficaz de un anticuerpo, opcionalmente, no sujeta a liofilizacion previa, un tampon que mantenga el pH en el rango de aproximadamente 4,0 a aproximadamente 6,0, y un tensioactivo opcional, los métodos para la preparacion de la formulacion y los métodos para utilizar la formulacion. Reivindicacion 1: Una formulacion farmacéutica acuosa estable, donde la formulacion comprende una cantidad terapéuticamente eficaz de un anticuerpo en un tampon de arginina, pH 4,0 a 6,0. Reivindicacion 24: La formulacion de la reivindicacion 1, donde el anticuerpo es un anticuerpo monoclonal. Reivindicacion 31: La formulacion de la reivindicacion 30 donde el anticuerpo es bevacizumab.
ARP100104778A 2009-12-21 2010-12-20 Formacion de anticuerpos AR079556A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28853509P 2009-12-21 2009-12-21

Publications (1)

Publication Number Publication Date
AR079556A1 true AR079556A1 (es) 2012-02-01

Family

ID=43733329

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104778A AR079556A1 (es) 2009-12-21 2010-12-20 Formacion de anticuerpos

Country Status (19)

Country Link
US (5) US20110226650A1 (es)
EP (2) EP2515941B1 (es)
JP (3) JP6214161B2 (es)
KR (3) KR20170087538A (es)
CN (2) CN102770158B (es)
AR (1) AR079556A1 (es)
AU (1) AU2010339770B2 (es)
BR (1) BR112012013093A2 (es)
CA (1) CA2783846C (es)
ES (1) ES2765657T3 (es)
IL (1) IL219537B (es)
MX (2) MX361668B (es)
MY (1) MY159156A (es)
PL (1) PL2515941T3 (es)
RU (2) RU2609658C2 (es)
SG (3) SG10201705886SA (es)
TW (2) TWI623323B (es)
WO (1) WO2011084750A1 (es)
ZA (1) ZA201203242B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1043320A1 (zh) 1999-06-01 2002-09-13 Biogen, Inc. Vla-1的一种阻塞性单系抗体，以及其治疗炎性失调的功用
PL367324A1 (en) 2001-04-13 2005-02-21 Biogen, Inc. Antibodies to vla-1
EP2034830B1 (en) 2006-05-25 2014-09-03 Biogen Idec MA Inc. Anti-vla-1 antibody for treating stroke
ES2765657T3 (es) * 2009-12-21 2020-06-10 Hoffmann La Roche Formulación farmacéutica de bevacizumab
WO2012141978A2 (en) * 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations with reduced viscosity
WO2013040196A2 (en) 2011-09-14 2013-03-21 Immunovative Therapies, Ltd. Automated device for biologic drug distribution
HK1201191A1 (en) * 2011-12-16 2015-08-28 辉瑞公司 Combination of inotuzumab ozogamicin and torisel for the treatment of cancer
MX370199B (es) * 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
KR20150024301A (ko) 2012-05-25 2015-03-06 노파르티스 아게 생물학적 치료제 및 구아니딘 또는 구아니딘 유도체를 함유하는 수성 약제학적 조성물 및 당해 조성물을 포함하는 주사제
TWI610861B (zh) * 2012-09-13 2018-01-11 梵提夫免疫療法公司 用於生物藥品分配的自動化裝置
AU2013322614A1 (en) * 2012-09-27 2015-04-02 Octapharma Ag Test for hemolytic potential of pharmaceutical products and formulations for risk minimization
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CN105209069B (zh) 2013-03-13 2019-08-23 豪夫迈·罗氏有限公司 抗体配制剂
CN103385852B (zh) * 2013-08-06 2015-03-11 南京正大天晴制药有限公司 一种盐酸法舒地尔注射液及其制备方法
WO2015071348A1 (en) * 2013-11-18 2015-05-21 Formycon Ag Pharmaceutical composition of an anti-vegf antibody
WO2015134406A1 (en) * 2014-03-03 2015-09-11 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
CN104906576B (zh) * 2014-03-13 2018-06-19 四川科伦博泰生物医药股份有限公司 可供皮下注射的高浓度抗vegf抗体配制剂
WO2016044334A1 (en) 2014-09-15 2016-03-24 Genentech, Inc. Antibody formulations
TWI705827B (zh) 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
CN104922668B (zh) * 2014-12-10 2019-08-23 信达生物制药(苏州)有限公司 一种稳定的抗vegf抗体制剂及其用途
EP3250596A1 (en) * 2015-01-28 2017-12-06 Pfizer Inc Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
CN107537036A (zh) * 2016-06-27 2018-01-05 江苏泰康生物医药有限公司 一种抗人血管内皮生长因子单克隆抗体的药物制剂及其应用
WO2018063963A1 (en) 2016-09-28 2018-04-05 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
CN106918658B (zh) * 2017-01-22 2020-01-31 合肥拓锐生物科技有限公司 一种阿昔替尼原料及其制剂中有关物质的分析方法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
US12234280B2 (en) 2018-03-05 2025-02-25 Janssen Pharmaceutica Nv Anti-PHF-tau antibodies and uses thereof
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
AU2020348947B2 (en) 2019-09-16 2025-11-27 Amgen Inc. Method for external sterilization of drug delivery device
CN112618482A (zh) * 2019-09-24 2021-04-09 江苏恒瑞医药股份有限公司 新型蛋白制剂
AU2020364480A1 (en) * 2019-10-08 2022-03-31 Samsung Bioepis Co., Ltd. Stable liquid composition, method for preparing same, and formulation comprising same
WO2021079337A1 (en) * 2019-10-23 2021-04-29 Cadila Healthcare Limited Pharmaceutical formulation of anti-her2 antibody and preparation thereof
IL299822A (en) * 2020-07-14 2023-03-01 Janssen Pharmaceutica Nv A blood-based test to detect tauopathy or amyloidogenic disease
AU2021367878A1 (en) * 2020-10-26 2023-06-22 Janssen Pharmaceutica Nv Methods of reducing tau in human subjects
WO2025101487A1 (en) * 2023-11-06 2025-05-15 Bruker Cellular Analysis, Inc. Affinity assay for microfluidic devices

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
EP1238986B1 (en) 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
ES2332893T3 (es) 1996-08-30 2010-02-15 Upfront Chromatography A/S Aislamiento de inmunoglobulinas.
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US20080318254A9 (en) 1997-03-10 2008-12-25 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
SI0973804T1 (sl) 1997-04-07 2007-06-30 Genentech Inc Proti-VEGF protitelesa
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DK1325932T5 (da) 1997-04-07 2005-10-03 Genentech Inc Anti-VEGF antistoffer
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
EP1064027B1 (en) * 1998-03-27 2008-06-18 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
AU754808B2 (en) 1999-03-30 2002-11-28 Amgen Fremont Inc. Method for preparing Monoclonal Antibody
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
ATE303445T1 (de) 1999-10-04 2005-09-15 Medicago Inc Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2005519580A (ja) 2001-05-16 2005-07-07 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ 非ヒト動物由来のヒト抗肺炎球菌抗体
CA2456648C (en) 2001-08-23 2011-08-16 Genmab A/S Human antibodies specific for interleukin 15 (il-15)
AU2004303792A1 (en) 2003-12-08 2005-07-07 Immunogen, Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US20060258841A1 (en) 2003-01-17 2006-11-16 Josef Michl Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AR044302A1 (es) 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
CA2526398C (en) 2003-05-21 2014-07-15 Medarex, Inc. Human monoclonal antibodies against bacillus anthracis protective antigen
EP2246333B1 (en) 2003-05-22 2012-10-24 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
RS20170595A1 (sr) 2003-05-30 2017-09-29 Genentech Inc Tretman sa anti-vegf antitelima
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
RU2365382C2 (ru) * 2004-04-14 2009-08-27 Дженентек, Инк. Композиции и способы для регуляции развития сосудов
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
KR101317235B1 (ko) * 2006-04-21 2013-10-15 조마 테크놀로지 리미티드 길항제 항-ｃｄ40 항체 제약 조성물
CA2654584A1 (en) * 2006-06-05 2007-12-21 Genentech, Inc. Extending survival of cancer patients with elevated levels of egf or tgf-alpha
US20100311655A1 (en) * 2007-06-07 2010-12-09 Mdrna, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
CA2692165A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
EP2173163A4 (en) * 2007-07-06 2010-12-08 Glaxosmithkline Llc ANTIBODY FORMULATIONS
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN102414221A (zh) * 2009-03-06 2012-04-11 健泰科生物技术公司 抗体配制剂
ES2765657T3 (es) * 2009-12-21 2020-06-10 Hoffmann La Roche Formulación farmacéutica de bevacizumab

Also Published As

Publication number Publication date
MX361668B (es) 2018-12-11
SG10201705886SA (en) 2017-08-30
CN107095846A (zh) 2017-08-29
RU2012131354A (ru) 2014-01-27
RU2017102553A (ru) 2018-12-19
TWI623323B (zh) 2018-05-11
MX2012006831A (es) 2012-08-17
JP6214161B2 (ja) 2017-10-18
JP2013515071A (ja) 2013-05-02
KR20190067275A (ko) 2019-06-14
CA2783846C (en) 2021-01-19
AU2010339770B2 (en) 2015-02-12
TW201130509A (en) 2011-09-16
TW201636048A (zh) 2016-10-16
CN102770158A (zh) 2012-11-07
JP2018035170A (ja) 2018-03-08
US20160251422A1 (en) 2016-09-01
RU2609658C2 (ru) 2017-02-02
MY159156A (en) 2016-12-15
KR20120108982A (ko) 2012-10-05
IL219537B (en) 2019-07-31
EP2515941B1 (en) 2019-11-13
SG2014011340A (en) 2014-07-30
KR20170087538A (ko) 2017-07-28
BR112012013093A2 (pt) 2017-12-12
EP3616719A1 (en) 2020-03-04
EP2515941A1 (en) 2012-10-31
SG181834A1 (en) 2012-07-30
ZA201203242B (en) 2013-07-31
JP6527038B2 (ja) 2019-06-05
US20110226650A1 (en) 2011-09-22
AU2010339770A1 (en) 2012-06-21
WO2011084750A1 (en) 2011-07-14
KR101989628B1 (ko) 2019-06-14
JP2015232001A (ja) 2015-12-24
CA2783846A1 (en) 2011-07-14
US20200392220A1 (en) 2020-12-17
US9226961B2 (en) 2016-01-05
ES2765657T3 (es) 2020-06-10
PL2515941T3 (pl) 2020-04-30
US20180171004A1 (en) 2018-06-21
US20140099301A1 (en) 2014-04-10
IL219537A0 (en) 2012-06-28
CN102770158B (zh) 2016-10-19

Similar Documents

Publication Publication Date Title
AR079556A1 (es) Formacion de anticuerpos
AR130402A2 (es) Formulaciones de anticuerpos anti-pdl1
AR095396A1 (es) Formulaciones de anticuerpo
CR11005A (es) Formulaciones estables de anticuerpos
CL2020002010A1 (es) Uso de un polipéptido que comprende una hormona de crecimiento, y ctps adheridos a la misma, para inducir crecimiento o ganancia de peso. (divisional solicitud 201400254)
CL2012001966A1 (es) Formulación farmacéutica que comprende entre 100-150 mg/ml de un anticuerpo que se une específicamente al receptor a de il-17 humana, una solución acuosa de un buffer 5-30 mm de ácido glutámico ph 4,5-5,2, prolina 2-4% p/v y polisorbato-20 0,005-0,02% p/v; envase farmacéutico y kit que comprende dicha formulación; y su uso para tratar psoriasis.
CY1120398T1 (el) Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη
AR076640A1 (es) Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
PE20191242A1 (es) Formulaciones de anticuerpo y metodos
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
AR086823A1 (es) Formulaciones de anticuerpo anti-c-met, metodos
CO6361952A2 (es) Formulación de anticuerpo
AR091961A1 (es) Inmunoconjugados y anticuerpos anti-etbr (receptor de endotelina b)
CL2008001984A1 (es) Formulacion de anticuerpo anti-cd20; y su uso para tratar enfermedades que implican celulas que expresan cd20 en un mamifero.
CL2013003214A1 (es) Formulacion estable que comprende al menos un anticuerpo monoclonal que se une especificamente a pcsk9, un tampon, un surfactante y al menos un estabilizador; y su uso para tratar o prevenir enfermedades relacionadas con el colesterol.
ECSP10010433A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes ácidas
AR059922A1 (es) Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
AR082630A1 (es) Anticuerpos anti-tenascina-c a2 y metodos de uso
PE20171512A1 (es) Anticuerpos anti-fap
MX2015015152A (es) Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13.
CL2012003172A1 (es) Formulacion liquida esteril que comprende una inmunoglobulina anti-esclerostina y acetato de calcio; su uso; y metodo para reducir la viscosidad de una formulacion de proteina.
CL2012003657A1 (es) Formulacion estable que comprende la proteina iduronato -2- sulfatasa y un tensoactivo de polisorbato; contenedor que comprende dicha formulacion; uso de dicha formulacion para tratar sindrome de hunters.
CR10561A (es) Vacunas para malaria
EA201391729A1 (ru) Состав, содержащий антитело
MX2016004926A (es) Formulaciones de tampon para la estabilidad de anticuerpo mejorada.

Legal Events

Date Code Title Description
FB Suspension of granting procedure